Yes, I think I would absolutely consider it. I think there is emerging evidence that it is of some benefit. There are some challenges with it, especially the practicalities, but definitely, as time has gone on, if you can get patients onto combination monoclonal antibodies early enough, there may be some benefit. Whether the trade-off between the cost and logistical challenges proves adequate for the benefit is something that needs to be decided.
On May 28th, 2021. See this statement in context.